title: Discontinuation of rivastigmine in routine clinical practice.
abstract: BACKGROUND
  Rivastigmine is used for symptomatic treatment of mild-to-moderately severe Alzheimer's Dementia (AD). We investigated the frequency of and reasons for rivastigmine discontinuation in clinical practice and possible predictive factors for discontinuation within the first six months after starting therapy.
  
  
  METHODS
  A retrospective cohort study was performed in rivastigmine users, who started therapy in a naturalistic setting. A nurse supported a part of the studied cohort, as this was introduced during the study period. Reasons for discontinuation were investigated, including therapy discontinuation if the Maximum Achieved Dose (MAD) was below 6 mg daily. Predictors of discontinuation within the first half year were investigated by logistic regression analysis.
  
  
  RESULTS
  Baseline Mini-Mental-State-Examination (MMSE) of included patients (n = 154) was 20.1, mean age was 78.4 years and 70% was female. Within 6 months, 61 users (39.6%) discontinued therapy, primarily (59.0%) for adverse events. Thereafter, the main reason for discontinuation was non-response according to clinimetrics. A MAD during the titration phase of 1.5-4.5 mg/day and absence of nurse support are significantly related to discontinuation within 6 months.
  
  
  CONCLUSIONS
  Rivastigmine is primarily discontinued within the first six months for intolerable adverse events and thereafter mainly for ongoing deterioration. A MAD of 1.5-4.5 mg/day and the absence of nurse support are independently related to discontinuation of rivastigmine within the initial 6 months.
authors.affiliation: Department of Geriatric Medicine, Slotervaart Hospital, Amsterdam, The Netherlands. apsfr@slz.nl
authors.forename: Suzanne V
authors.initials: SV
authors.lastname: Frankfort
authors.forename: Bregje A
authors.initials: BA
authors.lastname: Appels
authors.forename: Anthonius
authors.initials: A
authors.lastname: de Boer
authors.forename: Linda R
authors.initials: LR
authors.lastname: Tulner
authors.forename: Jos P C M
authors.initials: JP
authors.lastname: van Campen
authors.forename: Cornelis H W
authors.initials: CH
authors.lastname: Koks
authors.forename: Jos H
authors.initials: JH
authors.lastname: Beijnen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000451:nursing; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009483:Neuropsychological Tests; D010352:Patient Dropouts; D048448:Phenylcarbamates / Q000009:adverse effects* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D000068836:Rivastigmine; D017211:Treatment Failure
chemical_list: D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine